Prelude Therapeutics Inc
PRLDLatest QuantConomy context for PRLD: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.
Prelude Therapeutics Inc
QuantConomy has a structured record for PRLD. More descriptive asset metadata will appear here when the platform record includes it.
- Symbol
- PRLD
- Name
- Prelude Therapeutics Inc
- Coverage
- 3 market/data records
- Sources
- alphavantage fmp alpaca sec nasdaq
Recent signals for PRLD
Scored rows are pulled from the same signal API used by the digests.
| Signal | Direction | Score | Observed | Reason |
|---|---|---|---|---|
| earnings release | neutral | 40 | Mar 10, 12:00 AM | PRLD filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-03-10. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| earnings release | neutral | 40 | May 12, 12:00 AM | PRLD filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-05-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read). |
| ten percent owner | neutral | 38 | Jun 10, 08:46 PM | BAKER BROS. ADVISORS LP (Director, 10% Owner) was granted PRLD shares (undisclosed value) - 38000 shares - [weak neutral signal] |
EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).
Market coverage
| Market | Exchange | Source | Asset record |
|---|---|---|---|
| PRLD | NASDAQ | alphavantage | Prelude Therapeutics Inc |
| PRLD | NASDAQ | fmp | Prelude Therapeutics Incorporated |
| PRLD | NASDAQ | alpaca | Prelude Therapeutics Incorporated Common Stock |
Recent insider transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Jun 9, 2026 | Dorton Katina | Director | grant | 38,000 | — | — | 4 on EDGAR |
| Jun 9, 2026 | FRIEDMAN PAUL A | Director | grant | 38,000 | — | — | 4 on EDGAR |
| Jun 9, 2026 | BAKER BROS. ADVISORS LP | Director, 10% owner | grant | 38,000 | — | — | 4 on EDGAR |
| Jun 9, 2026 | Sandor Victor | Director | grant | 38,000 | — | — | 4 on EDGAR |
| Jun 9, 2026 | Bonita David P | Director, 10% owner | grant | 38,000 | — | — | 4 on EDGAR |
| Jun 9, 2026 | Babler Martin | Director | grant | 38,000 | — | — | 4 on EDGAR |
| May 1, 2026 | Morris Charles Q | Chief Medical Officer | grant | 450,000 | $4.70 | $2,115,000 | 4 on EDGAR |
| Apr 27, 2026 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | other | 1,407,000 | — | — | 4 on EDGAR |
| Apr 21, 2026 | BAKER BROS. ADVISORS LP | Director, 10% owner | purchase | 114,601 | $4.44 | $508,817 | 4 on EDGAR |
| Apr 21, 2026 | Bonita David P | Insider | purchase | 1,689,189 | $4.44 | $7,499,999 | 4 on EDGAR |
| Apr 21, 2026 | ORBIMED ADVISORS LLC | Insider | purchase | 1,689,189 | $4.44 | $7,499,999 | 4 on EDGAR |
| — | RA CAPITAL MANAGEMENT, L.P. | 10% owner | — | — | — | — | 3 on EDGAR |
| — | Brusky Sean P. | Chief Business Officer | — | — | — | — | 3 on EDGAR |
| Feb 4, 2026 | Scherle Peggy | Chief Scientific Officer | grant | 230,000 | — | — | 4 on EDGAR |
| Feb 4, 2026 | Vaddi Krishna | CEO | grant | 837,000 | — | — | 4 on EDGAR |
| Feb 4, 2026 | Lim Bryant David | CLO, CFO, Corp Sec. | grant | 275,000 | — | — | 4 on EDGAR |
| Feb 4, 2026 | Combs Andrew | Chief Chemistry Officer | grant | 230,000 | — | — | 4 on EDGAR |
Source: SEC filings via QuantConomy. Not investment advice.
Query PRLD context like a database.
These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.
More: All insider trades · How to read a Form 4 · API access